Health/Science/Wellness, Psychedelics

#222: Tim Schlidt, Palo Santo

Cannabinoid Connect 222: Tim Schlidt, Palo Santo

Tim Schlidt is the Co-Founder and Partner at Palo Santo, the leading U.S.-based psychedelic investment fund.

Topics Discussed:

  • The mental health crisis and psychedelics
  • Intersection of psychedelics and technology
  • Pure plant-derived medicine vs. chemically-synthesized compounds
  • Psychedelics investment landscape

Listen to the full episode

Watch on YouTube

This Episode is Sponsored By Regrow

This Episode is Sponsored By Endocanna Health

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *